![Eduard Goñalons](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Eduard Goñalons
Directeur/Membre du Conseil chez Kintsugi Therapeutics
Postes actifs de Eduard Goñalons
Sociétés | Poste | Début | Fin |
---|---|---|---|
Kintsugi Therapeutics
![]() Kintsugi Therapeutics Pharmaceuticals: MajorHealth Technology Kintsugi Therapeutics is a biomedical start-up based in Barcelona, Spain. The Spanish company focuses on developing innovative therapies for the treatment of liver conditions and other pathologies by targeting the regulation of endoplasmic reticulum stress. The company's lead candidate is a first-in-class endoplasmic reticulum stress inhibitor being developed for the treatment of non-alcoholic steatohepatitis (NASH). The company was founded by Carmen Herrero and Marc Cusachs, with Carmen Herrero serving as the CEO since incorporation. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Eduard Goñalons
Statistiques
Internationale
Espagne | 2 |
Opérationnelle
Director/Board Member | 1 |
Sectorielle
Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 1 |
---|---|
Kintsugi Therapeutics
![]() Kintsugi Therapeutics Pharmaceuticals: MajorHealth Technology Kintsugi Therapeutics is a biomedical start-up based in Barcelona, Spain. The Spanish company focuses on developing innovative therapies for the treatment of liver conditions and other pathologies by targeting the regulation of endoplasmic reticulum stress. The company's lead candidate is a first-in-class endoplasmic reticulum stress inhibitor being developed for the treatment of non-alcoholic steatohepatitis (NASH). The company was founded by Carmen Herrero and Marc Cusachs, with Carmen Herrero serving as the CEO since incorporation. | Health Technology |
- Bourse
- Insiders
- Eduard Goñalons
- Expérience